Source link : https://www.newshealth.biz/health-news/a-new-option-to-treat-intermediate-hepatocellular-carcinoma/
BARCELONA — Adding lenvatinib and pembrolizumab to transarterial chemoembolization (TACE) led to a significant improvement in progression-free survival in patients with intermediate-stage hepatocellular carcinoma compared with TACE plus placebo, according to findings from the first interim analysis of the phase 3 LEAP-012 study. The results, presented here at the European Society for Medical Oncology, could […]
Author : News Health
Publish date : 2024-09-15 14:26:12
Copyright for syndicated content belongs to the linked Source.